104 related articles for article (PubMed ID: 20084711)
1. Comparison of whole body scintigraphy with Tc-99m-methoxyisobutylisonitrile and iodine-131 NA in patients with differentiated thyroid cancer.
Al Saleh K; Safwat R; Al-Shammeri I; Abdul Naseer M; Hooda H; Al-Mohannadi S
Gulf J Oncolog; 2007 Jan; 1(1):29-33. PubMed ID: 20084711
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of technetium-99m methoxisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na scintigraphy, and serum thyroglobulin quantitation.
Dadparvar S; Chevres A; Tulchinsky M; Krishna-Badrinath L; Khan AS; Slizofski WJ
Eur J Nucl Med; 1995 Nov; 22(11):1330-8. PubMed ID: 8575487
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 99mTc-methoxyisobutyl isonitrile and 201Tl scintigraphy for detection of residual thyroid cancer after 131I ablative therapy.
Seabold JE; Gurll N; Schurrer ME; Aktay R; Kirchner PT
J Nucl Med; 1999 Sep; 40(9):1434-40. PubMed ID: 10492361
[TBL] [Abstract][Full Text] [Related]
4. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
[TBL] [Abstract][Full Text] [Related]
5. Clinical importance of technetium-99m-methoxyisobutylisonitrile (MIBI) scintigraphy in differentiated thyroid carcinoma patients with elevated thyroglobulin levels and negative I-131 scanning results.
Küçük NO; Külak HA; Aras G
Ann Nucl Med; 2006 Jul; 20(6):393-7. PubMed ID: 16922467
[TBL] [Abstract][Full Text] [Related]
6. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
Lind P; Gallowitsch HJ
Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
[TBL] [Abstract][Full Text] [Related]
7. Clinical usefulness of 99mTc-MIBI scintigraphy in the postsurgical evaluation of patients with differentiated thyroid cancer.
Campennì A; Violi MA; Ruggeri RM; Sindoni A; Moleti M; Vermiglio F; Baldari S
Nucl Med Commun; 2010 Apr; 31(4):274-9. PubMed ID: 20087239
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 201Tl, 99Tcm-MIBI and 131I imaging in the follow-up of patients with well-differentiated thyroid carcinoma.
Uğur O; Kostakoğlu L; Caner B; Güler N; Gülaldi NC; Ozmen M; Uysal U; Elahi N; Erbengi G; Bejdik C
Nucl Med Commun; 1996 May; 17(5):373-7. PubMed ID: 8736512
[TBL] [Abstract][Full Text] [Related]
9. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
[TBL] [Abstract][Full Text] [Related]
10. Comparison of FDG-PET and technetium-99m MIBI SPECT to detect metastatic cervical lymph nodes in well-differentiated thyroid carcinoma with elevated serum HTG but negative I-131 whole body scan.
Wu HS; Huang WS; Liu YC; Yen RF; Shen YY; Kao CH
Anticancer Res; 2003; 23(5b):4235-8. PubMed ID: 14666632
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of technetium-99m-MIBI scintigraphy in metastatic differentiated thyroid cancer--comparison study with 131I and 201Tl].
Nagamachi S; Jinnouchi S; Nishii R; Flores LG; Nakahara H; Futami S; Tamura S; Toshimori H; Kawai K
Kaku Igaku; 2000 Mar; 37(2):89-98. PubMed ID: 10783567
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.
Giusti M; Zoccola R; Guazzini B; Molinari E; Valenti S; Villa G; Bertolazzi L; Minuto F
Minerva Endocrinol; 2003 Sep; 28(3):191-203. PubMed ID: 14605601
[TBL] [Abstract][Full Text] [Related]
13. 99mTc-sestamibi and 131I whole-body scintigraphy and initial serum thyroglobulin in the management of differentiated thyroid carcinoma.
Ng DC; Sundram FX; Sin AE
J Nucl Med; 2000 Apr; 41(4):631-5. PubMed ID: 10768563
[TBL] [Abstract][Full Text] [Related]
14. Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma.
Lind P; Gallowitsch HJ; Langsteger W; Kresnik E; Mikosch P; Gomez I
J Nucl Med; 1997 Mar; 38(3):348-52. PubMed ID: 9074515
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of technetium-99m-MIBI scintigraphy in metastatic differentiated thyroid carcinoma.
Miyamoto S; Kasagi K; Misaki T; Alam MS; Konishi J
J Nucl Med; 1997 Mar; 38(3):352-6. PubMed ID: 9074516
[TBL] [Abstract][Full Text] [Related]
16. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of technetium-99m methoxyisobutyl isonitrile (99mTc-MIBI) scintigraphy in detecting thyroid cancer metastases: a critical evaluation.
Alam MS; Kasagi K; Misaki T; Miyamoto S; Iwata M; Iida Y; Konishi J
Thyroid; 1998 Dec; 8(12):1091-100. PubMed ID: 9920363
[TBL] [Abstract][Full Text] [Related]
18. Technetium-99m tetrofosmin uptake in insular thyroid carcinoma. A comparison with iodine-131.
Degirmenci B; Aydin A; Comlekci A; Ozdogan O; Bekis R
Clin Nucl Med; 2003 May; 28(5):385-8. PubMed ID: 12702934
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity of [99mTc]methoxyisobutylisonitrile scan in patients with metastatic differentiated thyroid cancer.
Ronga G; Ventroni G; Montesano T; Filesi M; Ciancamerla M; Di Nicola AD; Travascio L; Vestri AR; Signore A
Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):364-71. PubMed ID: 17473819
[TBL] [Abstract][Full Text] [Related]
20. [99m-Tc-MIBI for recurrent and metastatic differentiated thyroid carcinoma].
Elser H; Henze M; Hermann C; Eckert W; Mende U
Nuklearmedizin; 1997 Jan; 36(1):7-12. PubMed ID: 9082340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]